Catalyst Dossier · compiled by CeliA 🧫

SOPHiA GENETICS SA (SOPH)

Services-Computer Processing & Data Preparation · market cap $448M · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

SOPHiA GENETICS (SOPH) is a Swiss-founded, dual-headquartered (Rolle/Boston) data-driven medicine software company providing genomic, radiomic, and multimodal analytics to hospitals, labs, and biopharma. Notably, the supplied 'pipeline' (PRO-122 in glaucoma, PRO-148 in dry eye, etc.) is an ophthalmic drug-development pipeline that does not match a software/data-analytics business model — this is a material inconsistency in the source data that must be flagged rather than relied upon. The only scheduled catalyst is Q2 earnings on 2026-08-04.

The catalyst path

2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Sodium Hyaluronate Ophthalmic 0.4% BID	Phase 2	Dry Eye
Difluprednate 0.05%	Phase 3	Cataract
Lucentis®	Phase 3	Diabetic Macular Edema
Alleance®	Phase 3	Myopia
Moxifloxacin / Dexamethasone Ophthalmic Solution	Phase 3	Cataract Extraction
PRO-122	Phase 3	Primary Open Angle Glaucoma
Nanodrop®	Phase 2	Dry Eye
PRO-155	Phase 2	Cataract
dorzolamide-timolol-brimonidine	Phase 2	Primary Open Angle Glaucoma
PRO-148	Phase 3	Dry Eye
PRO-148 Ophthalmic Solution	Phase 2	Dry Eye Syndrome
PRO-157	Phase 2	Bacterial Conjunctivitis

Price & technical context

3-month

+5.1%

6-month

+13.1%

12-month

+62.6%

52-wk range

$2.99–$5.98

vs 50-day MA

+4.6%

vs 200-day MA

+12.2%

Realized vol

66.0%

Max drawdown

-48.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SOPH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.